Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00951899 · ClinicalTrials.gov registry record · Phase 4
The Effect of Welchol on Glucose Metabolism in Type 2 Diabetics
A Phase 4 study, sponsored by Mayo Clinic.
- Completed
- Registry status
- Phase 4
- Development phase
- 38
- Enrollment target
NCT00951899: Completed Phase 4 study, sponsored by Mayo Clinic.
NCT00951899 is a Phase 4 study that has completed, run by Mayo Clinic. The registered enrollment target is 38 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00951899, a Phase 4 study, has completed, sponsored by Mayo Clinic.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 38 participants
- Enrollment target
Study Summary
The goal of this study was to determine the metabolic mechanism for a certain type medication's ability to lower blood sugar after a meal in Type 2 Diabetics, in order to develop a better understanding of it's potential role in the treatment of obesity.
Interventions
- OTHER Placebo
- DRUG Metformin
- BEHAVIORAL Diet
- DRUG Colesevelam
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 38 participants |
| Start Date | 2009-08 |
| Est. Completion | 2012-12 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00951899
The ClinicalTrials.gov registry entry for NCT00951899 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 38 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Mayo Clinic, which has 2,844 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which Placebo is the first listed.
NCT00951899 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00951899 about?
NCT00951899 is a clinical study titled "The Effect of Welchol on Glucose Metabolism in Type 2 Diabetics". The goal of this study was to determine the metabolic mechanism for a certain type medication's ability to lower blood sugar after a meal in Type 2 Diabetics, in order to develop a better understanding of it's potential role in the treatment of obesity.
What is the current status of trial NCT00951899?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 38 participants. The study started on 2009-08. Estimated completion is 2012-12.
What interventions are being tested in trial NCT00951899?
The interventions under investigation include: Placebo (OTHER), Metformin (DRUG), Diet (BEHAVIORAL), Colesevelam (DRUG).
Who is sponsoring clinical trial NCT00951899?
This trial is sponsored by Mayo Clinic, which has 2,844 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.